Table 1 Correlation between RGN mRNA expression and clinicopathologic features in TCGA database.
From: RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma
Clinical features | RGN expression | P-value | |
|---|---|---|---|
Low (%) | High (%) | ||
Age | |||
 ≤ 70 | 116 (42.8) | 90 (33.2) | 0.017* |
 > 70 | 155 (57.2) | 181 (66.8) |  |
Gender | |||
 Female | 57 (21.0) | 85 (31.4) | 0.009* |
 Male | 214 (79.0) | 186 (68.6) |  |
Race | |||
 White | 245 (90.4) | 244 (90.0) | 0.633 |
 Black/African American | 22 (8.1) | 20 (7.4) |  |
 Asian | 4 (1.5) | 7 (2.6) |  |
Laterality | |||
 Bilateral | 247 (89.8) | 241 (87.3) | 0.424 |
 Left | 12 (4.4) | 11 (4.0) |  |
 Right | 16 (5.8) | 24 (8.7) |  |
Tumor stage | |||
 Stage I | 111 (41.0) | 160 (59.0) | 0.001* |
 Stage II | 109 (40.2) | 66 (24.4) |  |
 Stage III | 49 (18.1) | 39 (14.4) |  |
 Stage IV | 2 (0.7) | 6 (2.2) |  |
Pathologic M stage | |||
 M0 | 267 (98.5) | 262 (96.7) | 0.160 |
 M1 | 4 (1.5) | 9 (3.3) |  |
Pathologic N stage | |||
 N0 | 160 (59.0) | 189 (69.7) | 0.027* |
 N1 | 84 (31.0) | 55 (20.3) |  |
 N2 | 26 (9.6) | 17 (6.3) |  |
 N3 | 1 (0.4) | 10 (3.7) |  |
Pathologic T stage | |||
 T1 | 53 (19.6) | 70 (25.8) | 0.085 |
 T2 | 164 (60.5) | 156 (57.6) |  |
 T3 | 42 (15.5) | 33 (12.2) |  |
 T4 | 12 (4.4) | 12 (4.4) |  |
Radiation therapy | |||
 Yes | 35 (12.9) | 28 (10.3) | 0.348 |
 No | 236 (87.1) | 243 (89.7) |  |
New tumor event after initial treatment | |||
 Yes | 71 (26.2) | 74 (27.3) | 0.771 |
 No | 200 (73.8) | 197 (72.4) |  |
Cigarettes per day exposures | |||
 ≤ 3 | 156 (57.6) | 177 (65.3) | 0.064 |
 > 3 | 115 (42.4) | 94 (34.7) |  |
Prior malignancy diagnosis | |||
 Yes | 32 (11.8) | 34 (12.5) | 0.793 |
 No | 239 (88.2) | 237 (87.5) |  |
